Skeptic critique for analysis AD-MASTER-PLAN-TREM2-20260428030753: AD Master Plan preregistration: TREM2
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: TREM2 activation can be stage-dependent and may worsen inflammatory injury outside the right disease window.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across TREM2, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.
A decisive falsifier would be failure of stage-stratified TREM2 gain-of-function perturbation with microglial lipid handling, plaque compaction, and tau propagation endpoints to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.